Article

FDA advises patient notification

The FDA advises health-care professionals to follow up with patients for whom they administered an injectable product purchased from or produced by NECC.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Over 300 patients randomized in Ocular Therapeutix's SOL-1 phase 3 trial for OTX-TKI
December 4th 2024

Over 300 patients randomized in Ocular Therapeutix's SOL-1 phase 3 trial for OTX-TKI

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program
December 4th 2024

Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

PolyActiva’s PA5108 glaucoma implant shows promising results in clinical trial, paving the way for long-term drug delivery
December 3rd 2024

PolyActiva’s PA5108 glaucoma implant shows promising results in clinical trial, paving the way for long-term drug delivery

Prevent Blindness providing free educational resources on geographic atrophy
December 1st 2024

Prevent Blindness providing free educational resources on geographic atrophy

© 2024 MJH Life Sciences

All rights reserved.